Acquired nintedanib resistance in FGFR1-driven small cell lung cancer: Role of endothelin-A receptor-activated ABCB1 expression

Oncotarget

Volumn 7, Issue 31, 2016, Pages 50161-50179

  Englinger, Bernhard ^a   Lötsch, Daniela ^a   Pirker, Christine ^a   Mohr, Thomas ^a   van Schoonhoven, Sushilla ^a   Boidol, Bernd ^b   Lardeau, Charles Hugues ^b   Spitzwieser, Melanie ^c   Szabó, Pál ^d   Heffeter, Petra ^a   Lang, Irene ^e   Cichna Markl, Margit ^c   Grasl Kraupp, Bettina ^a   Marian, Brigitte ^a   Grusch, Michael ^a   Kubicek, Stefan ^b   Szakács, Gergely ^a,d   Berger, Walter ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b ERICH SCHMID INSTITUTE OF MATERIALS SCIENCE   (Austria)

^c UNIVERSITY OF VIENNA   (Austria)

^d INSTITUTE OF EXPERIMENTAL MEDICINE   (Hungary)

^e MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

ABCB1; Endothelin A receptor; FGFR1; Nintedanib; Small cell lung cancer

Indexed keywords

ENDOTHELIN A RECEPTOR; FIBROBLAST GROWTH FACTOR RECEPTOR 1; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MULTIDRUG RESISTANCE PROTEIN 1; NINTEDANIB; PROTEIN KINASE C; ABC TRANSPORTER SUBFAMILY B; ABCB1 PROTEIN, HUMAN; ANTINEOPLASTIC AGENT; ENDOTHELIN RECEPTOR; FGFR1 PROTEIN, HUMAN; INDOLE DERIVATIVE;

ABCB1 GENE; ARTICLE; BIOINFORMATICS; CANCER RESISTANCE; CARCINOGENICITY; CONTROLLED STUDY; DNA METHYLATION; DRUG EXPOSURE; DRUG SCREENING; GENE AMPLIFICATION; HUMAN; HUMAN CELL; LONG TERM EXPOSURE; MULTIDRUG RESISTANCE; NON SMALL CELL LUNG CANCER; PROMOTER REGION; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; SMALL CELL LUNG CANCER; TRANSCRIPTION REGULATION; ADENOCARCINOMA; CELL SEPARATION; CELL SURVIVAL; COMPARATIVE GENOMIC HYBRIDIZATION; DRUG RESISTANCE; FLOW CYTOMETRY; FLUORESCENCE IN SITU HYBRIDIZATION; GENE EXPRESSION REGULATION; LUNG TUMOR; METABOLISM; PHENOTYPE; TUMOR CELL LINE; TUMOR RECURRENCE;

ADENOCARCINOMA; ANTINEOPLASTIC AGENTS; ATP BINDING CASSETTE TRANSPORTER, SUB-FAMILY B; CELL LINE, TUMOR; CELL SEPARATION; CELL SURVIVAL; COMPARATIVE GENOMIC HYBRIDIZATION; DNA METHYLATION; DRUG RESISTANCE, NEOPLASM; FLOW CYTOMETRY; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; INDOLES; LUNG NEOPLASMS; NEOPLASM RECURRENCE, LOCAL; PHENOTYPE; RECEPTOR, FIBROBLAST GROWTH FACTOR, TYPE 1; RECEPTORS, ENDOTHELIN; SIGNAL TRANSDUCTION;

EID: 84981316474     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.10324     Document Type: Article

References (50)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA: a cancer journal for clinicians. 2011; 61:69-90.
2. Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA: a cancer journal for clinicians. 2015; 65:87-108.
3. Califano R, Abidin AZ, Peck R, Faivre-Finn C, Lorigan P. Management of small cell lung cancer: recent developments for optimal care. Drugs. 2012; 72:471-490.
4. Brody H. Lung cancer. Nature. 2014; 513:S1.
5. Caglevic C, Grassi M, Raez L, Listi A, Giallombardo M, Bustamante E, Gil-Bazo I, Rolfo C. Nintedanib in non-small cell lung cancer: from preclinical to approval. Therapeutic advances in respiratory disease. 2015; 9:164-172.
6. Heinzle C, Sutterluty H, Grusch M, Grasl-Kraupp B, Berger W, Marian B. Targeting fibroblast-growth-factor-receptordependent signaling for cancer therapy. Expert opinion on therapeutic targets. 2011; 15:829-846.
7. Coleman SJ, Bruce C, Chioni AM, Kocher HM, Grose RP. The ins and outs of fibroblast growth factor receptor signalling. Clinical science. 2014; 127:217-231.
8. Metzner T, Bedeir A, Held G, Peter-Vorosmarty B, Ghassemi S, Heinzle C, Spiegl-Kreinecker S, Marian B, Holzmann K, Grasl-Kraupp B, Pirker C, Micksche M, Berger W, et al. Fibroblast growth factor receptors as therapeutic targets in human melanoma: synergism with BRAF inhibition. The Journal of investigative dermatology. 2011; 131:2087-2095.
9. Beenken A, Mohammadi M. The FGF family: biology, pathophysiology and therapy. Nature reviews Drug discovery. 2009; 8:235-253.
10. Touat M, Ileana E, Postel-Vinay S, Andre F, Soria JC. Targeting FGFR Signaling in Cancer. Clinical cancer research. 2015; 21:2684-2694.
11. Carter EP, Fearon AE, Grose RP. Careless talk costs lives: fibroblast growth factor receptor signalling and the consequences of pathway malfunction. Trends in cell biology. 2015; 25:221-233.
12. Cihoric N, Savic S, Schneider S, Ackermann I, Bichsel-Naef M, Schmid RA, Lardinois D, Gugger M, Bubendorf L, Zlobec I, Tapia C. Prognostic role of FGFR1 amplification in early-stage non-small cell lung cancer. British journal of cancer. 2014; 110:2914-2922.
13. Weiss J, Sos ML, Seidel D, Peifer M, Zander T, Heuckmann JM, Ullrich RT, Menon R, Maier S, Soltermann A, Moch H, Wagener P, Fischer F, et al. Frequent and focal FGFR1 amplification associates with therapeutically tractable FGFR1 dependency in squamous cell lung cancer. Science translational medicine. 2010; 2:62ra93.
14. Heist RS, Mino-Kenudson M, Sequist LV, Tammireddy S, Morrissey L, Christiani DC, Engelman JA, Iafrate AJ. FGFR1 amplification in squamous cell carcinoma of the lung. Journal of thoracic oncology. 2012; 7:1775-1780.
15. Novello S, Kaiser R, Mellemgaard A, Douillard JY, Orlov S, Krzakowski M, von Pawel J, Gottfried M, Bondarenko I, Liao M, Barrueco J, Gaschler-Markefski B, Griebsch I, et al. Analysis of patient-reported outcomes from the LUME-Lung 1 trial: a randomised, double-blind, placebocontrolled, Phase III study of second-line nintedanib in patients with advanced non-small cell lung cancer. European journal of cancer. 2015; 51:317-326.
16. McCormack PL. Nintedanib: first global approval. Drugs. 2015; 75:129-139.
17. Redmond KL, Papafili A, Lawler M, Van Schaeybroeck S. Overcoming Resistance to Targeted Therapies in Cancer. Seminars in oncology. 2015; 42:896-908.
18. Hegedus T, Orfi L, Seprodi A, Varadi A, Sarkadi B, Keri G. Interaction of tyrosine kinase inhibitors with the human multidrug transporter proteins, MDR1 and MRP1. Biochimica et biophysica acta. 2002; 1587:318-325.
19. Heffeter P, Jakupec MA, Korner W, Chiba P, Pirker C, Dornetshuber R, Elbling L, Sutterluty H, Micksche M, Keppler BK, Berger W. Multidrug-resistant cancer cells are preferential targets of the new antineoplastic lanthanum compound KP772 (FFC24). Biochemical pharmacology. 2007; 73:1873-1886.
20. Gottesman MM, Ambudkar SV. Overview: ABC transporters and human disease. Journal of bioenergetics and biomembranes. 2001; 33:453-458.
21. Miklos W, Pelivan K, Kowol CR, Pirker C, Dornetshuber-Fleiss R, Spitzwieser M, Englinger B, van Schoonhoven S, Cichna-Markl M, Koellensperger G, Keppler BK, Berger W, Heffeter P. Triapine-mediated ABCB1 induction via PKC induces widespread therapy unresponsiveness but is not underlying acquired triapine resistance. Cancer letters. 2015; 361:112-120.
22. Bauer B, Hartz AM, Miller DS. Tumor necrosis factor alpha and endothelin-1 increase P-glycoprotein expression and transport activity at the blood-brain barrier. Molecular pharmacology. 2007; 71:667-675.
23. Wynes MW, Hinz TK, Gao D, Martini M, Marek LA, Ware KE, Edwards MG, Bohm D, Perner S, Helfrich BA, Dziadziuszko R, Jassem J, Wojtylak S, et al. FGFR1 mRNA and protein expression, not gene copy number, predict FGFR TKI sensitivity across all lung cancer histologies. Clinical cancer research. 2014; 20:3299-3309.
24. Schultheis AM, Bos M, Schmitz K, Wilsberg L, Binot E, Wolf J, Buttner R, Schildhaus HU. Fibroblast growth factor receptor 1 (FGFR1) amplification is a potential therapeutic target in small-cell lung cancer. Modern pathology, Inc. 2014; 27:214-221.
25. Jiang T, Gao G, Fan G, Li M, Zhou C. FGFR1 amplification in lung squamous cell carcinoma: a systematic review with meta-analysis. Lung cancer. 2015; 87:1-7.
26. Berger W, Setinek U, Mohr T, Kindas-Mugge I, Vetterlein M, Dekan G, Eckersberger F, Caldas C, Micksche M. Evidence for a role of FGF-2 and FGF receptors in the proliferation of non-small cell lung cancer cells. International journal of cancer, Journal international du cancer. 1999; 83:415-423.
27. Noguchi K, Katayama K, Sugimoto Y. Human ABC transporter ABCG2/BCRP expression in chemoresistance: basic and clinical perspectives for molecular cancer therapeutics. Pharmacogenomics and personalized medicine. 2014; 7:53-64.
28. Shukla S, Chen ZS, Ambudkar SV. Tyrosine kinase inhibitors as modulators of ABC transporter-mediated drug resistance. Drug resistance updates: reviews and commentaries in antimicrobial and anticancer chemotherapy. 2012; 15:70-80.
29. Wu CP, Hsiao SH, Su CY, Luo SY, Li YQ, Huang YH, Hsieh CH, Huang CW. Human ATP-Binding Cassette transporters ABCB1 and ABCG2 confer resistance to CUDC-101, a multi-acting inhibitor of histone deacetylase, epidermal growth factor receptor and human epidermal growth factor receptor 2. Biochemical pharmacology. 2014; 92:567-576.
30. Sarkadi B, Homolya L, Szakacs G, Varadi A. Human multidrug resistance ABCB and ABCG transporters: participation in a chemoimmunity defense system. Physiological reviews. 2006; 86:1179-1236.
31. Colabufo NA, Contino M, Niso M, Berardi F, Leopoldo M, Perrone R. EGFR tyrosine kinase inhibitors and multidrug resistance: perspectives. Frontiers in bioscience. 2011; 16:1811-1823.
32. Brozik A, Hegedus C, Erdei Z, Hegedus T, Ozvegy-Laczka C, Szakacs G, Sarkadi B. Tyrosine kinase inhibitors as modulators of ATP binding cassette multidrug transporters: substrates, chemosensitizers or inducers of acquired multidrug resistance? Expert opinion on drug metabolism & toxicology. 2011; 7:623-642.
33. Xiang QF, Wang F, Su XD, Liang YJ, Zheng LS, Mi YJ, Chen WQ, Fu LW. Effect of BIBF 1120 on reversal of ABCB1-mediated multidrug resistance. Cellular oncology. 2011; 34:33-44.
34. Patel A, Tiwari AK, Chufan EE, Sodani K, Anreddy N, Singh S, Ambudkar SV, Stephani R, Chen ZS. PD173074, a selective FGFR inhibitor, reverses ABCB1-mediated drug resistance in cancer cells. Cancer chemotherapy and pharmacology. 2013; 72:189-199.
35. Shen DW, Cardarelli C, Hwang J, Cornwell M, Richert N, Ishii S, Pastan I, Gottesman MM. Multiple drug-resistant human KB carcinoma cells independently selected for highlevel resistance to colchicine, adriamycin, or vinblastine show changes in expression of specific proteins. The Journal of biological chemistry. 1986; 261:7762-7770.
36. Triller N, Korosec P, Kern I, Kosnik M, Debeljak A. Multidrug resistance in small cell lung cancer: expression of P-glycoprotein, multidrug resistance protein 1 and lung resistance protein in chemo-naive patients and in relapsed disease. Lung cancer. 2006; 54:235-240.
37. Berger W, Setinek U, Hollaus P, Zidek T, Steiner E, Elbling L, Cantonati H, Attems J, Gsur A, Micksche M. Multidrug resistance markers P-glycoprotein, multidrug resistance protein 1, and lung resistance protein in non-small cell lung cancer: prognostic implications. Journal of cancer research and clinical oncology. 2005; 131:355-363.
38. Burger H, van Tol H, Brok M, Wiemer EA, de Bruijn EA, Guetens G, de Boeck G, Sparreboom A, Verweij J, Nooter K. Chronic imatinib mesylate exposure leads to reduced intracellular drug accumulation by induction of the ABCG2 (BCRP) and ABCB1 (MDR1) drug transport pumps. Cancer biology & therapy. 2005; 4:747-752.
39. Sugano T, Seike M, Noro R, Soeno C, Chiba M, Zou F, Nakamichi S, Nishijima N, Matsumoto M, Miyanaga A, Kubota K, Gemma A. Inhibition of ABCB1 Overcomes Cancer Stem Cell-like Properties and Acquired Resistance to MET Inhibitors in Non-Small Cell Lung Cancer. Molecular cancer therapeutics. 2015; 14:2433-2440.
40. Mizuuchi H, Suda K, Sato K, Tomida S, Fujita Y, Kobayashi Y, Maehara Y, Sekido Y, Nishio K, Mitsudomi T. Collateral chemoresistance to anti-microtubule agents in a lung cancer cell line with acquired resistance to erlotinib. PloS one. 2015; 10:e0123901.
41. Hashida S, Yamamoto H, Shien K, Miyoshi Y, Ohtsuka T, Suzawa K, Watanabe M, Maki Y, Soh J, Asano H, Tsukuda K, Miyoshi S, Toyooka S. Acquisition of cancer stem celllike properties in non-small cell lung cancer with acquired resistance to afatinib. Cancer science. 2015; 106:1377-1384.
42. Rosano L, Spinella F, Bagnato A. Endothelin 1 in cancer: biological implications and therapeutic opportunities. Nature reviews Cancer. 2013; 13:637-651.
43. Huang L, Hu C, Di Benedetto M, Varin R, Liu J, Wang L, Vannier JP, Jin J, Janin A, Lu H, Li H. Induction of multiple drug resistance in HMEC-1 endothelial cells after longterm exposure to sunitinib. OncoTargets and therapy. 2014; 7:2249-2255.
44. Sonpavde G, Willey CD, Sudarshan S. Fibroblast growth factor receptors as therapeutic targets in clear-cell renal cell carcinoma. Expert opinion on investigational drugs. 2014; 23:305-315.
45. Decleves X, Amiel A, Delattre JY, Scherrmann JM. Role of ABC transporters in the chemoresistance of human gliomas. Current cancer drug targets. 2006; 6:433-445.
46. Mathieu V, Pirker C, Schmidt WM, Spiegl-Kreinecker S, Lotsch D, Heffeter P, Hegedus B, Grusch M, Kiss R, Berger W. Aggressiveness of human melanoma xenograft models is promoted by aneuploidy-driven gene expression deregulation. Oncotarget. 2012; 3:399-413. doi: 10.18632/oncotarget.473.
47. Fischer H, Taylor N, Allerstorfer S, Grusch M, Sonvilla G, Holzmann K, Setinek U, Elbling L, Cantonati H, Grasl-Kraupp B, Gauglhofer C, Marian B, Micksche M, et al. Fibroblast growth factor receptor-mediated signals contribute to the malignant phenotype of non-small cell lung cancer cells: therapeutic implications and synergism with epidermal growth factor receptor inhibition. Molecular cancer therapeutics. 2008; 7:3408-3419.
48. Zhang JH, Chung TD, Oldenburg KR. A Simple Statistical Parameter for Use in Evaluation and Validation of High Throughput Screening Assays. Journal of biomolecular screening. 1999; 4:67-73.
49. Laszlo V, Hoda MA, Garay T, Pirker C, Ghanim B, Klikovits T, Dong YW, Rozsas A, Kenessey I, Szirtes I, Grusch M, Jakopovic M, Samarzija M, et al. Epigenetic down-regulation of integrin alpha7 increases migratory potential and confers poor prognosis in malignant pleural mesothelioma. The Journal of pathology. 2015; 237:203-214.
50. Puujalka E, Heinz M, Hoesel B, Friedl P, Schweighofer B, Wenzina J, Pirker C, Schmid JA, Loewe R, Wagner EF, Berger W, Petzelbauer P. Opposing roles of JNK and p38 in lymphangiogenesis in melanoma. The Journal of investigative dermatology. 2016; 136:967-977.